LuoxinPharmaceutical(002793)
Search documents
罗欣药业(002793) - 2017 Q3 - 季度财报
2017-10-20 16:00
Financial Performance - Operating revenue for the reporting period was ¥192,290,503.57, representing a year-on-year growth of 30.55%[9] - Net profit attributable to shareholders was ¥28,016,939.07, up 24.29% from the same period last year[9] - The net profit after deducting non-recurring gains and losses was ¥27,285,561.21, reflecting a 23.57% increase year-on-year[9] - Basic earnings per share were ¥0.14, an increase of 27.27% compared to the same period last year[9] - The net profit for the year-to-date period reached ¥92,985,735.73, which is a 23.80% increase compared to the same period last year[9] - The estimated net profit attributable to shareholders for 2017 is projected to be between 106 million and 131 million RMB, representing a growth of 5.62% to 30.53% compared to 2016's net profit of 100.36 million RMB[24] Assets and Liabilities - Total assets at the end of the reporting period reached ¥825,787,272.91, an increase of 1.59% compared to the end of the previous year[9] - Cash and cash equivalents at the end of Q3 2017 were CNY 68.66 million, a decrease of 36.01% from CNY 107.30 million at the end of Q3 2016, primarily due to land acquisition and cash dividend payments[20] - Accounts receivable increased by 58.05% to CNY 168.07 million in Q3 2017 from CNY 106.34 million in Q3 2016, driven by sales growth[20] - The company’s intangible assets increased by 158.53% to CNY 192.51 million in Q3 2017, mainly due to the acquisition of land use rights[20] - The company’s short-term borrowings increased to CNY 10 million, reflecting a rise in short-term working capital loans[20] Cash Flow - The net cash flow from operating activities was -¥10,455,506.85, a decline of 67.10% year-on-year[9] - The net cash flow from operating activities decreased by 75.68% to CNY 2.13 million in the first nine months of 2017, compared to CNY 8.76 million in the same period of 2016[20] Shareholder Information - The company reported a total of 21,409 shareholders at the end of the reporting period[13] - The largest shareholder, Fang Xiubao, holds 37.54% of the shares, totaling 75,074,800 shares[13] Investments and Projects - The company plans to invest in a project to construct an annual production capacity of 2 million submersible pumps, approved by the board and shareholders[21] - The increase in production capacity from the 1 million units per year submersible pump project, which commenced operations at the end of 2016, is expected to lower procurement and production costs, thereby enhancing profitability[24] - The company intends to publicly issue convertible bonds totaling no more than CNY 281.32 million, with a maturity of 6 years from the issuance date[21] Financial Expenses and Taxation - Financial expenses for Q3 2017 were CNY 5.90 million, a significant increase due to foreign exchange losses from the depreciation of the US dollar against the RMB[19] - The company reported a 218.17% increase in tax and additional fees for the first nine months of 2017, totaling CNY 6.95 million, due to changes in VAT deductions[19] Fair Value and Losses - The company reported a fair value loss of 6,000 RMB on futures investments, with an initial investment of 50,007,000 RMB and a year-end amount of 45,492,000 RMB[26] Return on Equity - The weighted average return on equity was 3.91%, a decrease of 0.50% compared to the previous year[9]
罗欣药业(002793) - 2017 Q2 - 季度财报
2017-08-07 16:00
Financial Performance - The company's operating revenue for the first half of 2017 was approximately RMB 433.12 million, representing a 27.97% increase compared to RMB 338.46 million in the same period last year[18]. - The net profit attributable to shareholders of the listed company was approximately RMB 64.97 million, up 23.59% from RMB 52.57 million year-on-year[18]. - The net profit after deducting non-recurring gains and losses was approximately RMB 61.34 million, reflecting a 32.96% increase from RMB 46.13 million in the previous year[18]. - The company reported a total investment of 673,577,303.00 CNY for the construction of a manufacturing project with an annual capacity of 1 million submersible pumps[50]. - The company reported a total comprehensive income of 64,966,870 RMB for the current period[156]. Assets and Liabilities - The company's total assets at the end of the reporting period were approximately RMB 930.55 million, a 14.47% increase from RMB 812.89 million at the end of the previous year[18]. - The total liabilities reached RMB 227,249,892.68, up from RMB 114,559,170.83, reflecting a substantial increase of about 98.3%[126]. - The company's equity attributable to shareholders rose to RMB 703,302,366.42 from RMB 698,333,569.76, showing a slight increase of about 0.7%[127]. - The company's current assets totaled RMB 522,354,213.29, slightly down from RMB 526,400,696.15 at the beginning of the period, indicating a decrease of about 0.9%[125]. - The total assets reached ¥935,180,970.00, compared to ¥817,184,847.22 in the previous year, indicating growth in the company's asset base[134]. Cash Flow - The company reported a net cash flow from operating activities of approximately RMB 37.17 million, down 10.46% from RMB 41.51 million in the same period last year[18]. - The company's cash flow from operating activities decreased by 10.46% to ¥37,169,965.85 from ¥41,512,518.51 year-on-year[38]. - Cash inflow from financing activities was CNY 91,278,800.00, down from CNY 313,467,096.50, a decrease of approximately 70.9%[143]. - Net cash flow from financing activities was CNY 14,239,308.87, a decline from CNY 171,020,724.22, reflecting a decrease of about 91.7%[143]. - The ending cash and cash equivalents balance was CNY 150,707,523.22, compared to CNY 132,834,682.05 in the previous period, showing an increase of approximately 13.4%[143]. Share Capital and Dividends - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company completed a capital increase, raising its total share capital from 100 million shares to 200 million shares, with a registered capital change from RMB 100 million to RMB 200 million[17]. - Basic earnings per share decreased from 0.65 yuan to 0.32 yuan after the share change[104]. - Diluted earnings per share also decreased from 0.65 yuan to 0.32 yuan post share change[104]. - The total share capital increased from 100 million shares to 200 million shares due to the capital reserve conversion[103]. Research and Development - Research and development expenses increased by 26.17% to ¥15,832,987.83 from ¥12,549,371.89 year-on-year, reflecting the company's commitment to innovation[38]. - The company has strengthened its technology research and development and expanded sales regions, leading to steady growth in sales revenue and profit[25]. - The company holds 62 patents and has developed high-tech products such as solar submersible pumps and high-efficiency pumps[28]. - The company plans to invest approximately ¥118,013.20 million in a new project to produce 2 million submersible pumps annually, enhancing production capacity[35]. - The company aims to enhance market competitiveness by improving cost management and resource utilization[74]. Market Position and Strategy - The core product, submersible pumps, accounted for approximately 82% of the company's main business revenue in 2016[35]. - The company has established long-term stable partnerships with over 100 clients across Africa, Asia, and Europe[25]. - The company has a competitive advantage in technology, quality, and brand, positioning it as a leader in the domestic submersible pump industry[26]. - The company aims to enhance its market influence globally while accelerating domestic market expansion[34]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[148]. Governance and Compliance - The company has not engaged in any major litigation or arbitration matters during the reporting period[83]. - There were no significant penalties or rectification measures during the reporting period[84]. - The company has not conducted any precision poverty alleviation work or plans for such initiatives in the reporting period[97]. - The financial report for the first half of 2017 was not audited, indicating that the figures presented are preliminary and subject to change[122]. - The company has not reported any significant changes in accounting policies regarding derivatives compared to the previous reporting period[59]. Future Outlook - The company reported a net profit attributable to shareholders for the first three quarters of 2017 expected to be between 85 million and 100 million yuan, representing a year-on-year increase of 13.17% to 33.14%[72]. - The company aims to match futures hedging with production needs to mitigate price volatility risks[58]. - The overall financial performance indicates a robust position for future investments and strategic initiatives[148]. - The company has not experienced any changes in the feasibility of its projects during the reporting period[65]. - The company has not changed any fundraising projects during the reporting period[65].
罗欣药业(002793) - 2017 Q1 - 季度财报
2017-04-23 16:00
Financial Performance - The company's revenue for Q1 2017 was ¥190,049,184.54, representing a 35.19% increase compared to ¥140,574,232.17 in the same period last year[8] - Net profit attributable to shareholders was ¥24,660,054.05, up 58.77% from ¥15,531,735.42 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥22,563,350.75, a 53.46% increase from ¥14,702,932.02 in the previous year[8] - The basic earnings per share increased by 19.05% to ¥0.25 from ¥0.21 in the same period last year[8] - The net profit attributable to shareholders for the first half of 2017 is expected to range from ¥55 million to ¥80 million, representing a growth of 4.63% to 52.19% compared to the same period in 2016[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥922,911,221.44, a 13.53% increase from ¥812,892,740.59 at the end of the previous year[8] - The net assets attributable to shareholders increased by 3.53% to ¥722,993,623.81 from ¥698,333,569.76 at the end of the previous year[8] - Short-term borrowings increased to ¥41,395,800.00, reflecting a rise in trade financing loans[15] Cash Flow and Financial Health - The net cash flow from operating activities was negative at -¥39,873,321.57, a significant decrease compared to ¥5,179,333.66 in the same period last year, reflecting an 869.85% decline[8] - The company's cash and cash equivalents increased by 33.51% to ¥187,079,834.43, primarily due to the redemption of bank wealth management products[15] - The financial expenses decreased by 65.27% to ¥802,700.87, primarily due to reduced borrowing interest[15] - The company recorded an investment income of ¥2,126,031.13 from the redemption of wealth management products[16] Receivables and Subsidies - Accounts receivable rose by 43.73% to ¥152,849,196.82, attributed to increased sales and outstanding customer payments[15] - The company received government subsidies amounting to ¥346,728.64 during the reporting period[9] - The company reported a significant increase of 1828.63% in other receivables, totaling ¥43,181,346.03, mainly due to land purchase deposits[15] - The cash outflow for other operating activities surged by 336.90% to ¥42,090,852.53, mainly due to land purchase deposits[15] Shareholder Information - The top shareholder, Fang Xiubao, holds 37.54% of the shares, while the second-largest shareholder, Li Xueqin, holds 10.17%[12] Investments and Future Projects - The company acquired land use rights for a plot in the Dongbu Industrial Cluster, which will be used for future fundraising projects[17] - Operating revenue for Q1 2017 was ¥190,049,184.54, a 35.19% increase compared to Q1 2016, driven by the production commencement of fundraising projects[15]
罗欣药业(002793) - 2016 Q4 - 年度财报
2017-03-19 16:00
Financial Performance - The company's operating revenue for 2016 was ¥637,397,258.54, representing a 9.10% increase compared to ¥584,211,860.09 in 2015[15]. - The net profit attributable to shareholders for 2016 was ¥100,362,781.97, which is a 22.71% increase from ¥81,787,382.39 in the previous year[15]. - The net cash flow from operating activities increased by 25.15% to ¥72,742,004.88 in 2016, up from ¥58,122,830.45 in 2015[15]. - Total assets at the end of 2016 reached ¥812,892,740.59, a 47.91% increase from ¥549,600,311.41 at the end of 2015[15]. - The net assets attributable to shareholders increased by 105.70% to ¥698,333,569.76 in 2016, compared to ¥339,496,382.20 in 2015[15]. - The basic earnings per share remained stable at ¥1.09, unchanged from the previous year[15]. - The company reported a significant fair value change gain of CNY 13.22 billion from trading financial assets, contrasting with a loss of CNY 4.76 billion in the previous year[20]. - The company’s non-current asset disposal loss was CNY 279.69 thousand, compared to a gain of CNY 19.82 million in 2015[20]. - The company achieved operating revenue of CNY 637.40 million in 2016, representing a 9.10% increase compared to the previous year[33]. - The net profit attributable to shareholders reached CNY 100.36 million, marking a 22.71% growth year-on-year[33]. Research and Development - Research and development investment amounted to CNY 24.29 million, an increase of 8.93% from the prior year[33]. - Research and development expenses amounted to ¥24,294,613.32, representing 3.81% of total revenue, with an increase of 8.93% from ¥22,302,580.35 in 2015[48]. - The company is focusing on developing new products such as solar-powered submersible pumps, which have started to gain market recognition[48]. - The company plans to enhance its R&D capabilities, focusing on high-efficiency variable frequency submersible pumps and fully automated unmanned pump station equipment[68]. Market Expansion - The company has established long-term stable partnerships with over 100 clients across Africa, Asia, and Europe, enhancing its market presence[24]. - The company’s sales strategy has expanded to include markets in Europe, America, and Southeast Asia, optimizing its market layout[33]. - The company expanded its market presence in Asia, with revenue increasing by 29.77% to ¥265,097,547.27, compared to ¥204,288,102.88 in 2015[37]. - The company is committed to maintaining a balance between shareholder liquidity and long-term investment stability through these commitments[80]. Cash Flow and Investments - Operating cash inflow increased by 18.73% to ¥750,073,019.63, while operating cash outflow rose by 18.08% to ¥677,331,014.75, resulting in a net cash flow from operating activities of ¥72,742,004.88, up 25.15%[50]. - Investment cash inflow surged by 41,378.47% to ¥13,625,478.85, primarily due to profits from copper futures contracts, while investment cash outflow increased by 309.78% to ¥171,005,426.82, mainly from increased investments in fundraising projects and bank wealth management products[50]. - Financing cash inflow grew by 80.04% to ¥353,474,405.59, attributed to funds raised from the initial public offering, with net cash flow from financing activities reaching ¥155,457,095.77, a staggering increase of 2,297.22%[50]. - The net increase in cash and cash equivalents was ¥68,157,847.95, reflecting a growth of 180.53% compared to the previous year, driven by operating and financing activities[50]. Shareholder Returns - The company plans to distribute a cash dividend of ¥6.00 per 10 shares, based on a total share capital of 100,000,000 shares as of December 31, 2016[4]. - The total distributable profit for the year 2016 is RMB 252,556,141.81, with a net profit of RMB 99,994,341.67 after statutory surplus reserve allocation[77]. - The cash dividend for 2016 represents 100% of the profit distribution total, reflecting a strong commitment to returning value to shareholders[77]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during its growth phase[77]. Governance and Compliance - The company emphasizes compliance with laws and regulations, ensuring accurate and timely information disclosure[113]. - The company has established independent financial, operational, and personnel systems, ensuring no dependency on the controlling shareholder for assets or operations[154]. - The company’s independent directors provided valuable suggestions on operational strategies and risk management, which were accepted by the management[159]. - The company has a robust governance structure that aligns with the regulatory requirements set by the China Securities Regulatory Commission[153]. Employee and Management Structure - The total number of employees in the company is 1,144, with 844 in production, 46 in sales, 121 in technical roles, 15 in finance, and 118 in administration[148]. - The company has a diverse board with members holding various professional backgrounds, including finance, engineering, and management[135][136][137][138][139]. - The independent directors include professionals with significant academic and industry experience, enhancing the company's governance[138][139]. - The company has implemented a comprehensive employee training program, integrating it into the performance evaluation system to enhance overall employee quality[150]. Financial Health - The company’s debt-to-asset ratio improved to 14.09%, a decrease of 24.14 percentage points from the previous year[122]. - The company’s financial condition has significantly improved, enhancing its investment and risk resistance capabilities[122]. - The company maintained effective internal control over financial reporting as of December 31, 2016, according to the internal control audit report[166]. - The audit opinion on the financial statements was standard and unqualified, reflecting fair presentation in all material respects[174].
罗欣药业(002793) - 2016 Q3 - 季度财报
2016-10-18 16:00
Financial Performance - Operating revenue for the period was ¥147,287,040.90, representing a year-on-year increase of 16.61%[7] - Net profit attributable to shareholders increased by 73.59% to ¥22,541,136.90 compared to the same period last year[7] - Basic earnings per share rose by 30.21% to ¥0.2254[7] - The estimated net profit attributable to shareholders for 2016 is projected to range from CNY 81.79 million to CNY 106.32 million, reflecting a change of 0.00% to 30.00% compared to the previous year[27] - The net profit for 2015 attributable to shareholders was CNY 81.79 million[27] Assets and Liabilities - Total assets increased by 48.67% to ¥817,117,617.88 compared to the end of the previous year[7] - Net assets attributable to shareholders increased by 98.26% to ¥673,078,310.28 compared to the end of the previous year[7] - Cash and cash equivalents increased by 291.63% to ¥107,299,727.93 compared to ¥27,398,263.18 in the previous year[16] - Monetary funds rose by 43.00% to ¥114,361,179.93, primarily due to unutilized funds from the IPO[15] - Inventory increased by 36.63% to ¥146,040,437.87, reflecting an increase in material reserves based on sales orders[15] - Prepayments surged by 354.68% to ¥36,367,649.66, mainly due to increased payments to suppliers[15] - Short-term borrowings decreased by 65.15% to ¥35,000,000.00, as the company had sufficient working capital[15] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,374[10] - The top shareholder, Fang Xiubao, holds 37.54% of the shares[10] - The company did not engage in any repurchase transactions during the reporting period[12] Cash Flow - The company reported a net cash flow from operating activities of ¥9,729,581.19, down 228.56% year-on-year[7] - Net cash flow from operating activities was ¥9,729,581.19, a significant change from -¥7,567,925.56 in the previous year[16] - The company received cash from government subsidies amounting to ¥8,760,635.66, an increase of 141.13%[16] Shareholding Commitments and Regulations - The company reported a commitment to not transfer or entrust the management of shares held directly or indirectly for a period of 36 months from the date of listing[18] - If the closing price falls below the IPO price for 20 consecutive trading days within six months post-listing, the lock-up period will automatically extend by six months[19] - Shareholders are restricted from transferring shares for 12 months post-listing, with a similar extension clause if the stock price conditions are not met[19] - The maximum number of shares that can be transferred annually by directors and senior management is limited to 25% of their total holdings during their tenure[19] - After the lock-up period, any share reduction must not exceed 50% of the total shares held by the individual[19] - The company has committed to ensuring that any share reduction price will not be lower than the IPO price during the first 24 months post-lock-up[19] - The company is actively managing its shareholding structure to comply with regulatory requirements and maintain investor confidence[18] - The company has outlined specific conditions under which share transfers can occur, ensuring transparency and adherence to market regulations[19] - The management team has established a clear framework for shareholding commitments to align with long-term company performance[19] - The company is focused on maintaining stability in its share price and investor relations through these commitments[18] Share Repurchase and Dividend Policy - The company has obligations to repurchase shares but has not yet proposed a repurchase plan[21] - The company plans to repurchase shares, with a total amount not exceeding RMB 100 million for each repurchase, and the total repurchase within 12 months not exceeding 3% of the total share capital[22] - The company aims for a cash dividend distribution of at least 20% of the distributable profit for the year, provided that cash flow is sufficient and will not affect future operations[23] - In the case of significant capital expenditures, the cash dividend proportion may be adjusted to a minimum of 40% if the company is in a mature stage with major spending plans[23] Investment Activities - The total initial investment cost for futures is 108,874,550.00, with a fair value change of 4,589,950.00 during the reporting period[29] - The total amount of futures contracts purchased during the period is 57,278,600.00, while the amount sold is 54,166,200.00, resulting in a net investment income of -1,394,623.19[29] - The total investment in other assets amounts to 118,538,344.45, with a fair value change of 6,140,655.55[29] - The cumulative investment income from other assets is reported as -5,270,500.00[29] - The total assets amount to 227,412,894.45, with a total fair value change of 10,730,605.55[29] Compliance and Governance - There are no instances of non-compliance with external guarantees during the reporting period[30] - There are no non-operating fund occupations by controlling shareholders or their affiliates reported during the period[31] - The company conducted an on-site investigation on September 8, 2016, with institutional investors[32]
罗欣药业(002793) - 2016 Q2 - 季度财报
2016-08-18 16:00
Financial Performance - The company's operating revenue for the first half of 2016 was ¥338,460,507.35, representing an increase of 11.06% compared to ¥304,743,496.90 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥52,566,385.59, up 6.26% from ¥49,467,616.24 in the previous year[20]. - The net cash flow from operating activities increased significantly by 67.93%, reaching ¥41,512,518.51 compared to ¥24,719,781.85 in the same period last year[20]. - Total assets at the end of the reporting period were ¥798,333,874.29, a 45.26% increase from ¥549,600,311.41 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company rose by 91.62%, amounting to ¥650,529,864.29 compared to ¥339,496,382.20 at the end of the previous year[20]. - Basic earnings per share decreased by 4.37% to ¥0.6308 from ¥0.6596 in the same period last year[20]. - The weighted average return on equity was 11.63%, down from 15.89% in the previous year[20]. Investment and Market Expansion - Research and development investment reached ¥12,549,371.89, up 28.09% from the previous year[32]. - The company is expanding its production capacity with the completion of the annual production project for 1 million submersible pumps, alleviating previous capacity constraints[34]. - The company is actively exploring new markets in Southeast Asia and Oceania while enhancing its domestic sales system[29]. - The company is focusing on developing high-efficiency, energy-saving, and environmentally friendly pump products to meet market demands[30]. - The company has made significant progress in the development of water-filled shielded submersible motors, laying a solid foundation for future market expansion[30]. Risk Management and Compliance - The company emphasizes the importance of investment risk awareness in its forward-looking statements[6]. - The company has established a comprehensive risk management system for futures hedging, including approval processes and internal controls[50]. - The company emphasizes the importance of matching foreign exchange hedging with actual business operations to avoid speculative trading[50]. - The independent directors confirmed that the company's copper futures hedging activities are conducted using self-owned funds and comply with relevant laws and regulations[50]. - The company strictly adhered to relevant laws and regulations, enhancing internal controls and information disclosure to improve governance standards[70]. Shareholder and Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. - The company has not distributed cash dividends or bonus shares in the previous year and plans to continue this approach for the current half-year[65][66]. - The company aims to distribute at least 20% of the annual distributable profits in cash dividends if conditions are met[97]. - The company plans to prioritize cash dividends when cash flow is sufficient and will propose mid-term cash dividends based on profitability[97]. - The company’s cash dividend policy emphasizes continuity and stability, with annual cash dividends proposed based on financial performance[98]. Financial Position and Assets - The total amount of raised funds is RMB 25,737 million, with a net amount of RMB 25,737 million after deducting issuance costs[54]. - The actual investment amount in fundraising projects as of June 30, 2016, is RMB 21,616.39 million, representing 87.55% of the committed investment for the annual production of 1 million submersible pumps[56]. - The company’s total assets increased significantly, reflecting a robust financial position[164]. - The company has a registered capital of 100,000,000 CNY with a total of 10,000,000 shares[164]. - The company operates in the general equipment manufacturing industry, focusing on pumps and vacuum equipment[164]. Corporate Governance and Compliance - There were no significant litigation or arbitration matters during the reporting period[71]. - The company did not engage in any asset acquisitions, sales, or mergers during the reporting period[75][76][77]. - There were no stock incentive plans or their implementations during the reporting period[78]. - The company did not have any related party transactions in daily operations or asset transactions[79][80][81][82][83]. - The company has not undergone any penalties or rectifications during the reporting period[102]. Accounting and Financial Reporting - The semi-annual financial report has not been audited[101]. - The financial statements were approved by the board on August 18, 2016, ensuring compliance with accounting standards[168]. - The company's accounting period runs from January 1 to December 31, with the current report covering January 1 to June 30, 2016[169]. - The company adopts the Chinese Yuan (RMB) as its functional currency for accounting purposes[171]. - The company recognizes foreign currency transactions at the exchange rate on the transaction date, with differences recorded in profit or loss[175].